Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine이종 프라임-부스트 COVID-19 백신 투여 6개월 후 오미크론을 포함한 다양한 SARS-CoV-2 변종에 대한 면역 반응Article Published on 2022-05-312022-09-11 Journal: Journal of Travel Medicine [Category] COVID19(2023년), SARS, 변종, [키워드] administration Alpha Analysis B.1 Beta Comparative Comparative analysis Covaxin COVID-19 vaccine Covishield delta variant Delta variants Follow-up groups Heterologous heterologous prime-boost heterologous vaccination Homologous vaccine IgG antibody NAb titer NAb titers neutralization omicron recipient reduction in responses against SARS-CoV-2 sera vaccinees variants variants of SARS-CoV-2 [DOI] 10.1093/jtm/taac033 PMC 바로가기 [Article Type] Article
SARS-CoV-2 Delta and delta derivatives impact on neutralization of Covishield recipient seraSARS-CoV-2 델타 및 델타 파생 상품이 Covishield 수혜자 혈청 중화에 미치는 영향Article Published on 2022-04-012022-09-11 Journal: The Journal of Infection [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Abstract AY.1 Covishield Delta Delta AY.1 derivative neutralization SARS-CoV-2 sera variant variant of concern [DOI] 10.1016/j.jinf.2022.02.018 PMC 바로가기 [Article Type] Article
An episode of transmission of COVID-19 from a vaccinated healthcare worker to co-workersArticle Published on 2022-04-012023-07-07 Journal: Infectious diseases (London, England) [Category] COVID19(2023년), [키워드] ChAdOx1 nCoV-19 COVID-19 Covishield RT-PCR Transmission Vaccine breakthrough [DOI] 10.1080/23744235.2021.2002929
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months6개월 후 백신 단독 또는 SARS-CoV-2 감염 + 백신(하이브리드 면역)에 의해 유도된 항체에 의한 오미크론(B.1.1.529) 변이체의 차선 중화Article Published on 2022-04-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI Against Anti-RBD IgG antibody B.1.1.529 BBV152 Biotechnology ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine correlation Covaxin Covishield cross-sectional cross-sectional study demonstrated Department exhibited explain foundation four group four groups geometric mean geometric mean titre GMT group groups hybrid Hybrid immunity Immune escape Immunity inactivated India individual Infection limit Live virus Live-virus neutralisation Melinda Gate Melinda Gates moderate natural infection nCoV neutralisation neutralisation assay neutralisation test neutralisation titre Neutralisation titres neutralise neutralising ability omicron Omicron variant outcome Primary outcome quantification Rapid reduction reduction in SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strain SARS-CoV-2 variant serum Significant Spread subjects tested titre USA vaccinated individual vaccinated individuals vaccination Vaccine variant virus Virus neutralisation [DOI] 10.1016/j.ebiom.2022.103938 PMC 바로가기 [Article Type] Article
Study of immunogenicity, safety and efficacy of covishield vaccine among health care workers in a tertiary cardiac care centre3차 심장치료센터 의료진을 대상으로 한 covishield 백신의 면역원성, 안전성 및 유효성 연구Article Published on 2022-04-012022-09-12 Journal: Indian journal of medical microbiology [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome Adverse Adverse events following immunisation (AEFI) average Breakthrough infection Care conducted coronavirus Covishield dose doses duration of symptom Efficacy event Fever HCWs Health care Health care worker Health care workers (HCWs) IgG antibody increase in interval local pain median value Mild pandemic participant post vaccination prevented reduced Research safety profile SARS-CoV-2 second dose Seropositivity severity Severity of infection Study participants Symptom uninfected vaccination Vaccine were assessed [DOI] 10.1016/j.ijmmb.2022.03.003 PMC 바로가기 [Article Type] Article
Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative reviewReview Published on 2022-02-222023-06-15 Journal: Immunologic research [Category] COVID19(2023년), MERS, SARS, [키워드] Covaxin COVID-19 Covishield immune response Vaccine [DOI] 10.1007/s12026-022-09265-0 PMC 바로가기 [Article Type] Review
Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study인도 의료 종사자들 사이에서 ChAdOx1-nCOV(Covishield™) 및 BBV-152(Covaxin™) 백신을 사용한 체액 항체 동역학: 6개월 종단면 코로나바이러스 백신 유도 항체 역가(COVAT) 연구Article Published on 2022-02-012022-09-12 Journal: Diabetes & metabolic syndrome [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] age Analysis anti-spike antibody antibody Antibody Response Antibody titer Antibody titre Blood Group body-mass cohorts Comorbidity conducted Covaxin COVID-19 Covishield cross-sectional Decline decrease dose Gender geometric mean GMT healthcare worker humoral humoral antibody Humoral response individual individuals Infection linear mixed model no difference participant Participants Quantitative recipient SARS-CoV-2 second dose Seropositivity significantly higher significantly more type 2 diabete Vaccine Vaccines were used [DOI] 10.1016/j.dsx.2022.102424 PMC 바로가기 [Article Type] Article
Comorbidities and Vaccination Status of COVID-19 All-Cause Mortality at a Tertiary Care Center of Western IndiaPreventive Medicine Published on 2022-01-302022-10-31 Journal: Cureus [Category] COVID-19, [키워드] all-cause mortality Autoimmune disorders Breakthrough infection cardiovascular Care center comorbid patients Comorbidities Comorbidity conducted Corona Covaxin Coverage COVID COVID-19 COVID-19 vaccine Covishield death deaths defined diabetes disease disease onset doses Efficacy first dose higher risk HIV hypertension include India less morbidity and mortality Mortality Neurological disorders occurred Other Patient positive COVID-19 Prevent proportion renal RT-PCR second dose severe disease shown smoking status Tertiary vaccinated individuals vaccination Vaccine [DOI] 10.7759/cureus.21721 PMC 바로가기 [Article Type] Preventive Medicine
Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 CovaxinArticle Published on 2021-12-292023-06-19 Journal: Journal of Travel Medicine [Category] Fulltext, SARS, [키워드] Covaxin Covishield Heterologous regime immunogenecity SARS-CoV-2 [DOI] 10.1093/jtm/taab166 PMC 바로가기
Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal StudyPreventive Medicine Published on 2021-11-252022-10-31 Journal: Cureus [Category] COVID-19, [키워드] acute respiratory syndrome Administered affecting age Analysis antibody antibody kinetics Antibody titer AstraZeneca vaccine average AZD1222 binding antibody unit blood sample BMI booster dose Breakthrough infection breakthrough infections ChAdOx1 chadox1 ncov19 vaccine ChAdOx1 vaccine chemiluminescence collected conducted coronavirus Coronavirus disease 2019 COVID vaccine COVID-19 COVID-19 vaccine Covishield dose doses Factor Factors first dose geometric globe healthcare facility Healthcare professional history IgG IgG titer immunoassay Immunoglobulin intramuscularly Kinetics linear mixed model longitudinal material Medical Science men Microparticle mixed model Nurses obese occurred Older overweight pandemic participant Person potential benefit Prospective Research Result SARS-CoV-2 SARS-COV-2 infection second dose seroreversion Seven shown tested the receptor-binding domain the spike protein the vaccine titer vaccination Vaccine vaccine dose viral particle women [DOI] 10.7759/cureus.19879 PMC 바로가기 [Article Type] Preventive Medicine